In a new Carolina Journal Exclusive, Associate Editor David N. Bass finds that the Life Sciences Development Act now before the short session of the General Assembly poses an additional risk to taxpayers. The new federal health care bill imposes new taxes on medical device manufacturers that will depress profits in some of the same businesses the LSD company would invest in.
For more on the LSD bill, click on the link.
